Skip to main content

CORRECTION article

Front. Cell Dev. Biol., 25 August 2022
Sec. Epigenomics and Epigenetics
Volume 10 - 2022 | https://doi.org/10.3389/fcell.2022.1009752
This article is part of the Research Topic Crosstalk between Epigenetics on the Development of Cancer and Cardiovascular Disease View all 6 articles

Corrigendum: Comprehensive pan-cancer analysis of the prognostic and immunological roles of METTL3/lncRNA-SNHG1/miRNA-140-3p/UBE2C axis

A correction has been applied to this article in:

  1. Corrigendum: Comprehensive pan-cancer analysis of the prognostic and immunological roles of the METTL3/lncRNA-SNHG1/miRNA-140-3p/UBE2C axis

    1. Read correction
Xiulin Jiang&#x;Xiulin Jiang1†Yixiao Yuan&#x;Yixiao Yuan2†Lin TangLin Tang2Juan WangJuan Wang2Qianqian LiuQianqian Liu2Xiaolan ZouXiaolan Zou2Lincan Duan Lincan Duan2*
  • 1Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences & Yunnan Province, Kunming Institute of Zoology, Kunming, China
  • 2Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, China

A Corrigendum on
Comprehensive pan-cancer analysis of the prognostic and immunological roles of the METTL3/lncRNA-SNHG1/miRNA-140-3p/UBE2C axis

by Jiang, X., Yuan, Y., Tang, L., Wang, J., Liu, Q., Zou, X., and Duan, L. (2021). Front. Cell Dev. Biol. 9:765772. doi: 10.3389/fcell.2021.765772

In the original article there was a mistake in the author affiliations for Xiulin Jiang which was erroneously presented as “Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, China”, it should instead be “Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences & Yunnan Province, Kunming Institute of Zoology, Kunming, China”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: m6A modification, SNHG1, miRNA-140-3p, UBE2C, pan-cancer, prognosis, immune cell infiltration, drug sensitivity

Citation: Jiang X, Yuan Y, Tang L, Wang J, Liu Q, Zou X and Duan L (2022) Corrigendum: Comprehensive pan-cancer analysis of the prognostic and immunological roles of METTL3/lncRNA-SNHG1/miRNA-140-3p/UBE2C axis. Front. Cell Dev. Biol. 10:1009752. doi: 10.3389/fcell.2022.1009752

Received: 02 August 2022; Accepted: 03 August 2022;
Published: 25 August 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Jiang, Yuan, Tang, Wang, Liu, Zou and Duan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Lincan Duan, duanmumuhuosan@163.com

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.